

Minutes of Pre-Bid Meeting
Year 2021-2022
Treatment of Poor Cancer Patients
MTI HMC

A Pre-Bid meeting regarding the tender for the Year 2021-2022 was held on Friday 16th July 2021 from 10:30 AM to 11:30 AM, in the conference room of Family Care Center, Hayatabad Medical Complex, Peshawar. Protocols and SOPs for Prevention of Covid 19 were followed.

The following attended the meeting:

1. Dr. Sadaf Chiragh, Associate Professor Medical Oncology Department MTI HMC, Chairperson Technical Committee.
2. Dr. Tariq Mehr, Associate Professor, Medical B Ward, MTI HMC, Member Technical Committee.
3. Mr. Abid Ali, Manager HR Department, MTI HMC, Member Technical Committee.
4. Dr Sufyan Ahmad, Registrar, Medical Oncology Department MTI HMC, Member Technical Committee.

Representatives of different Pharmaceutical Firms attended the meeting.

The meeting started with recitation of Holy Quran.

Dr. Sadaf Chiragh briefed the audience about

1. Key points of the BSD.
2. Technical Evaluation criteria.
3. Non eligibility of inclusion of un-registered medicines.
4. Date and time for submission and opening of Technical Bids.

Question answer session followed the end of the session.


The following decision were taken:

1. Date and time for submission and opening of Technical Bids remain the same as per Advertisement.
2. Any firm who requested for the optional addition of any drug in formulary or any new strength of a drug was accepted for those who contacted via email and/or submitted their request during the meeting (List of added Medicines is attached with) to be added to the formulary and uploaded on HMC Website for information.

S.NO	REQUESTED DRUG
01	Cap Palbociclib 75 mg, 100 mg, 125 mg
02	Cap Sunitinib 25 mg, 12.5 mg
03	Inj Ado Trastuzumab 100 mg, 160 mg
04	Inj Pegfilgrastim 6 mg
05	Inj Vinorelbine 10 mg, 50 mg
06	Cap Aprepitant 80 mg, 125 mg
07	Inj Leuprolide 11.25 mg
08	Inj Granisetron 3 mg

09	Tab Granisetron 1 mg
----	----------------------

The meeting ended with thanks to the Committee members.


Chairperson,
Technical Committee,
Treatment of Poor Cancer Patients
MTI HMC.